{
    "id": 27898,
    "fullName": "PDGFRA Y288C",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PDGFRA Y288C lies within the Ig-like C2-type domain 3 of the Pdgfra protein (UniProt.org). Y288C results in constitutive activation of Pdgfra and downstream signaling, and increased transformation and migration compared to wild-type PDGFRA in cell culture (PMID: 29533785, PMID: 30389923), and is associated with PDGFRA inhibitor resistance (PMID: 30389923).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                },
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5156,
        "geneSymbol": "PDGFRA",
        "terms": [
            "PDGFRA",
            "CD140A",
            "PDGFR-2",
            "PDGFR2"
        ]
    },
    "variant": "Y288C",
    "createDate": "04/29/2018",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": {
        "id": 119112,
        "transcript": "NM_006206",
        "gDna": "chr4:g.54267392A>G",
        "cDna": "c.863A>G",
        "protein": "p.Y288C",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17878,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17876,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Gleevec (imatinib) in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17877,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Sutent (sunitinib) in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17892,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) treatment resulted in decreased proliferation of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17891,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ISIS-STAT3rx (AZD9150) did not decrease viability of transformed cells expressing PDGFRA Y288C in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 2782,
                "therapyName": "AZD9150",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17879,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated resistance to Crenolanib in culture (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA Y288C demonstrated sensitivity to GSK2126458 (omipalisib) in culture, resulting in decreased cell proliferation (PMID: 30389923).",
            "molecularProfile": {
                "id": 29469,
                "profileName": "PDGFRA Y288C"
            },
            "therapy": {
                "id": 763,
                "therapyName": "GSK2126458",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15855,
                    "pubMedId": 30389923,
                    "title": "Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30389923"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29469,
            "profileName": "PDGFRA Y288C",
            "profileTreatmentApproaches": [
                {
                    "id": 18006,
                    "name": "PDGFR-alpha Inhibitor",
                    "profileName": "PDGFRA Y288C"
                },
                {
                    "id": 18005,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "PDGFRA Y288C"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119114,
            "transcript": "XM_005265743",
            "gDna": "chr4:g.54267392A>G",
            "cDna": "c.863A>G",
            "protein": "p.Y288C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119115,
            "transcript": "XM_011534385",
            "gDna": "chr4:g.54267392A>G",
            "cDna": "c.863A>G",
            "protein": "p.Y288C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119112,
            "transcript": "NM_006206",
            "gDna": "chr4:g.54267392A>G",
            "cDna": "c.863A>G",
            "protein": "p.Y288C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119113,
            "transcript": "XM_017008282",
            "gDna": "chr4:g.54267392A>G",
            "cDna": "c.863A>G",
            "protein": "p.Y288C",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}